Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis

Minerva Medica

Volumn 100, Issue 5, 2009, Pages 371-383

  Quinn, G P ^a,b   Vadaparampil, S T ^a,b   Bower, B ^a   Friedman, S ^c   Keefe, D L ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Facing Our Risk of Cancer Empowered FORCE   (United States)

Author keywords

Breast neoplasms; Decision making; Heredity; Ovarian neoplasms; Preimplantatlon diagnosis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER RISK; CRYOPRESERVATION; ETHICAL DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; INFERTILITY; MASTECTOMY; MENOPAUSE; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRACTICE GUIDELINE; PREIMPLANTATION GENETIC DIAGNOSIS; PREMATURE OVARIAN FAILURE; PRENATAL DIAGNOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; WHOLE BODY RADIATION;

BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PREIMPLANTATION DIAGNOSIS; PRENATAL DIAGNOSIS; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK ASSESSMENT;

EID: 77949538166     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
3. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-71.
4. Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol 2009;20:1653-9
5. Daly M, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S et al. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guideline, version 1.2006 [Internet] Available at http://nccn.org/ physician-gls/indiex.html. [cited 2006, Nov 19].
6. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
7. Weber B, Punzalan, Eisen A, et al. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2000;67(s2):59.
8. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91(17):1475-9.
9. Mincey BA.Genetics and the management of women at high risk for breast cancer 2003;8:466-473.
10. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecologic Oncology 2009;112:594-600.
11. Vadaparampil ST, Wey JP, Kinney AY. Psychosocial aspects of genetic counseling and testing. Semin Oncol Nurs 2004;20:186-95.
12. Vadaparampil ST, Ropka M, Stefanek ME. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers. Fam Cancer 2005;4:195-206.
13. Vadaparampil ST, Miree CA, Wilson C, Jacobsen PB. Psychosocial and behavioral impart of genetic counseling and testing. Breast Dis 2006;27:97-108.
14. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
15. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 2008;7:179-86.
16. Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005:83-6.
17. Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev 2004;13:733-40.
18. Fortuny D, Balmaña J, Graña B, Torres A, Ramón y Cajal T et al. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Hum Reprod 2009;24:1000-6.
19. Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 2009;91:2361-8
20. Claus E, Schildkraut J, Thompson D, Risch N. The genetic attributable risk of breast and ovarian cancer 1996;77:2318-24.
21. American Medical Association. Identifying and managing hereditary risk for breast and ovarian cancer. Chicago; 2001.
22. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V et al. BRCA1 and BRCA2 genetic testing in Hispanic patients:mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 2007;25:4635-41.
23. HFEA: Choices and Boundaries Report. 2006.
24. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-76.
25. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
26. Turtle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients:a trend toward more aggressive surgical treatment. J Clin Oncol 2007;25:5203-9.
27. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation. N Engl J Med 2002;346:1609-15
28. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An International Case-Control Study. J Clin Oncol 2005;23:7491-6.
29. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
30. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM.Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.Fam Cancer 2008;7:179-86.
31. Empowerment FFoRoC:Cancer Previvors.
32. Kenen R, Shapiro P, Friedman S, Coyne J. Peer-support in coping with medical uncertainty:discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psychooncology 2007;16:763-71.
33. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.Eur J Cancer 2002;38(Suppl 6):S15-7.
34. Roell S. Breast removal - the anguish of Sophie's choice. The Times. 23 February 2009.
35. Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
36. Briasoulis E, Ziogas D, Fatouros M. Prophylactic surgery in the complex decision-making management of BRCA mutation carriers. Ann Surg Oncol 2008;15:1788-90.
37. Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000;18:2484-92.
38. Madoff ET, Barnett RE, Bober SL. Unraveling the next chapter:sexual development, body image, and sexual functioning in female BRCA carriers. Cancer 2009;15:15-8.
39. Vadaparampil S, Quinn G, Knapp C, Malo TL, Friedman S. Factors associated with pgd acceptance among women concerned about hereditary breast and ovarian cancer. Genet Med. 2009 Aug 25. [Epub ahead of print].
40. Quinn G, Vadaparampil S, Jacobsen PB, Knapp C, Keefe D, Bell G. Frozen hope, fertilty preservation for women with cancer. J Midwifery Women's Health 2009; In Press.
41. Bresser PJC, Seynaeve C, Gool ARV, Brekelmans CT, Meijers-Heijboer H, van Geel AN et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 2006;117:1675-82
42. Lee S, Schover L, Partridge A. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31.
43. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-66.
44. Katz-Jaffe M, Gardner D. Syposium. Innovative techniques in human embryo viability assessment. Can proteomics help shape the future of human assisted conception? Reprod Biomen Online 2008;17:467-501.
45. LA. R. S. 9:2713 (2002).
46. Soini S, Ibarreta D, Anastasiadou V, Aymé S, Braga S, Cornel M et al. The interface between assisted reproductive technologies and genetics:technical, social, ethical and legal issues. Eur J Hum Genet 2006;14:588-645.
47. Baykal B, Korkmaz C, Ceyhan ST, Goktolga U, Baser I. Opinions of infertile Turkish women on gamete donation and gestational surrogacy. Fertil Steril 2008;89:817-22.
48. van den Akker OBA. Psychosocial aspects of surrogate motherhood. Hum Reprod Update 2007;13:53-62.
49. Reilly DR. Surrogate pregnancy:a guide for Canadian prenatal health care providers. CMAJ 2007;176:483-5.
50. nd edition. London: Taylor & Francis; 2004. p. 934.
51. Center AS:Legal overview of surrogacy laws by state. Marietta, GA: TASC; 1997. Available at http://www.surrogacy.com/legals/map.html. [cited 2009, Sep 15].
52. Smerdon U. Crossing bodies, crossing borders:international surrogacy between the United States and India. Cumberland Law Review 2008;39:15-85.
53. Kastrinos F, Stoffel EM, Balmana J, Syngal S. Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis. Am J Gastroenterol 2007;102:1284-90.
54. Paek B. Prenatal diagnosis. World J Surg 2003;27:27-37.
55. Quinn G, Vadaparampil S, Wilson C, et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril 2009;91:2361-8.
56. Ogilvie C, Braude P, Scriven P. Preimplantation genetic diagnosis- an overview. J of Histochem Cytochem 2005;53:255-60.
57. Baruch S, Kaufman D, Hudson K. Genetic testing of embryos:practices and perspectives of U.S. IVF clinics. Fertil Steril 2008;89:1053-8.
58. Marik JJ. Preimplantation genetic diagnosis. E-Medicine; 2005.
59. Marik J. Preimplantation genetic diagnosis. E-Medicine; 2005.
60. Coutelle C, Williams C, Handyside A, Hardy K, Winston R, Williamson R. Genetic analysis of DNA from single human oocytes:a model for preimplantation diagnosis of cystic fibrosis. Bmj 1989;299:22-4.
61. Holding C, Monk M. Diagnosis of beta-thalassaemia by DNA amplification in single blastomeres from mouse preimplantation embryos. Lancet 1989;2:532-5.
62. Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 1990;344:768-70.
63. Baruch S, Kaufman D, Hudson KL. Genetic testing of embryos:practices and perspectives of U.S. IVF clinics. Fertil Steril 2008;89:1053-8.
64. Simpson JL, Carson SA, Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. J Natl Cancer Inst Monogr 2005;87-90.
65. Allen C, Reardon W. Assisted reproduction technology and defects of genomic imprinting. Bjog 2005;112:1589-94.
66. Association AP. In vitro fertilization. IVF; 2007.
67. Piyamongkol W, Bermudez MG, Harper JC, Wells D. Detailed investigation of factors influencing amplification efficiency and allele drop-out in single cell PCR:implications for preimplantation genetic diagnosis. Mol Hum Reprod 2003;9:411-20.
68. Fragouli E. Preimplantation genetic diagnosis:present and future. J Assist Reprod Genet 2007;24:201-7.
69. Savulescu J, Hemsley M, Newson A, Foddy B. Behavioural genetics:why eugenic selection is preferable to enhancement. J Appl Philos 2006;23:157-71.
70. Niermeijer MF, de Wert G, Dondorp W. Preimplantation genetic diagnosis for cancer. Lancet Oncol 2006;7:794-5.
71. Hudson KL. Preimplantation genetic diagnosis:public policy and public attitudes. Fertil Steril 2006;85:1638-45.
72. Jones H. IFFS Surveillance 2007. Fertil Steril 2007;87(Suppl. 1):S1-67.
73. Menon U. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 2007;22:1573-7.
74. Quinn G, Vadaparampil S, King L, Miree C, Friedman S. Conflict between values and technology:perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. Fam Cancer. 2009 Jun 25. [Epub ahead of print]
75. Shahine LK, Kuppermann M, Davis G, Creasman J, Cedars MI. Patient willingness to participate in a clinical trial with preimplantation genetic diagnosis. Fertil Steril 2008;89:879-84.
76. Vadaparampil ST, Quinn GP, Knapp C, Malo TL, Friedman S. Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer. Genet Med 2009 Aug 25. [Epub ahead of print]
77. Schenker JG. Gender selection:cultural and religious perspectives. J Assist Reprod Genet 2002;19:400-10.
78. Fasouliotis SJ, Schenker JG. Cryopreservation of embryos:Medical, ethical, and legal issues. J Assist Reprod Genet 1996;13:756-61.
79. Schenker J. Sperm, oocyte, and pre-embryo donation. J Assist Reprod Genet 1995;12:499-508.
80. A Practice Committee Report. Preimplantation genetic diagnosis. Birmingham, AL: American Society for Reproductive Medicine; 2001.
81. Canada A, Schover L. Research promoting better patient education on reproductive health after cancer. J Natl Cancer Inst Monogr 2005:98-100.
82. Quinn G, Vadparampil S, Gwede C, Miree C, King LM, Clayton HB et al. Discussion of fertility preservation with newly diagnosed patients: Oncologist's views. J Cancer Surviv 2007;1:146-55.
83. Wallace WH. Fertility preservation for young people treated with cancer: what are the attitudes and knowledge of clinicians? Ped Blood Cancer 2006;48:2-3.
84. Zapzalka DM, Redmon JB, Pryor JL. A survey of oncologists regarding sperm cryopreservation and assisted reproductive techniques for male cancer patients. Cancer 1999;86:1812-7.
85. Zebrack BJ. Fertility issues for young adult survivors of childhood cancer. Psycho-Oncology 2004;13:689-99.
86. Aalfs C, Mollema E, Oort F, de Haes J, Leschot N, Smets E. Genetic counseling for familial conditions during pregnancy:an analysis of patient characteristics. Clin Genet 2004;66:112-21.
87. Burton P, Sanders K. Patient attitudes to donation of embryos for research in Western Australia. Med J Australia 2004;180:559-61.
88. deLacey S. Patients' attitudes to their embryos and their destiny:social conditioning? Best Pract Res Clin Obstet Gynaecol 2007;21:101-12.
89. Newton CR, Fisher J, Feyles V, Tekpetey F, Hughes L, Isacsson D. Changes in patient preferences in the disposal of cryopreserved embryos. Hum Reprod 2007;22:3124-8.
90. Peshkin B, Nusbaum R, DeMarco T. Genetic counseling about reproductive options for hereditary cancer: what is the standard of care? J Clin Oncol 2007;25:911-a-912.
91. Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors: potential reproductive implications. J Minim Invasive Gynecol 2009 Jul 14. [Epub ahead of print]
92. Eckmann KR, Kockler DR. Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome. Ann Pharmacother 2009;43:1338-46.
93. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-8.
94. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives:to use or not to use. Breast 2005;142:64-8.
95. Narod SA, Sun P, Risch HA;Hereditary Ovarian Cancer Clinical Study Group Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 2001;345:1706-7.